Esperion Reports Second Quarter 2025 Financial Results and Provides Business Update
Esperion (NASDAQ: ESPR) reported strong Q2 2025 financial results, with total revenue growing 12% year-over-year to $82.4 million. U.S. net product revenue increased 42% to $40.3 million, while total retail prescription equivalents grew 10% from Q1.
Key achievements include settlement agreements with three ANDA filers protecting NEXLETOL庐 until 2040, and the company's first-ever quarter of operating income ($15.0 million). Esperion expanded globally through partnerships in Japan, Europe, Canada, Israel, and Australia/New Zealand, with European royalty revenue increasing 30% sequentially to $13.6 million.
The company expects to achieve sustainable profitability beginning in Q1 2026 and maintains its 2025 operating expense guidance of $215-235 million.
Esperion (NASDAQ: ESPR) ha riportato solidi risultati finanziari nel secondo trimestre del 2025, con un fatturato totale in crescita del 12% su base annua, raggiungendo 82,4 milioni di dollari. Il ricavo netto dai prodotti negli Stati Uniti 猫 aumentato del 42%, arrivando a 40,3 milioni di dollari, mentre le equivalenti prescrizioni al dettaglio totali sono cresciute del 10% rispetto al primo trimestre.
Tra i principali traguardi si annoverano accordi di risoluzione con tre richiedenti ANDA che proteggono NEXLETOL庐 fino al 2040, e il primo trimestre di sempre con un reddito operativo positivo per l鈥檃zienda (15,0 milioni di dollari). Esperion ha ampliato la propria presenza globale tramite partnership in Giappone, Europa, Canada, Israele e Australia/Nuova Zelanda, con i ricavi da royalty europei che sono cresciuti del 30% rispetto al trimestre precedente, raggiungendo 13,6 milioni di dollari.
L鈥檃zienda prevede di raggiungere una redditivit脿 sostenibile a partire dal primo trimestre del 2026 e conferma la guida sulle spese operative per il 2025, stimata tra 215 e 235 milioni di dollari.
Esperion (NASDAQ: ESPR) report贸 s贸lidos resultados financieros en el segundo trimestre de 2025, con ingresos totales que crecieron un 12% interanual hasta 82,4 millones de d贸lares. Los ingresos netos por productos en EE.UU. aumentaron un 42% hasta 40,3 millones de d贸lares, mientras que los equivalentes totales de recetas al por menor crecieron un 10% respecto al primer trimestre.
Los logros clave incluyen acuerdos de conciliaci贸n con tres solicitantes de ANDA que protegen NEXLETOL庐 hasta 2040, y el primer trimestre con ingresos operativos para la compa帽铆a (15,0 millones de d贸lares). Esperion ampli贸 su presencia global mediante asociaciones en Jap贸n, Europa, Canad谩, Israel y Australia/Nueva Zelanda, con ingresos por regal铆as europeas que aumentaron un 30% secuencialmente hasta 13,6 millones de d贸lares.
La compa帽铆a espera alcanzar rentabilidad sostenible a partir del primer trimestre de 2026 y mantiene su gu铆a de gastos operativos para 2025 entre 215 y 235 millones de d贸lares.
鞐愳姢韼橂Μ鞓� (NASDAQ: ESPR)鞚� 2025雲� 2攵勱赴 臧曤牓頃� 鞛 鞁れ爜鞚� 氤搓碃頄堨溂氅�, 齑� 毵れ稖鞚� 鞝勲厔 雽�牍� 12% 歃濌皜頃� 8,240毵� 雼煬毳� 旮半頄堨姷雼堧嫟. 氙戈淡 雮� 靾滌牅頀� 毵れ稖鞚� 42% 歃濌皜頃� 4,030毵� 雼煬鞓�瓿�, 齑� 靻岆Г 觳橂癌 霌标皜霟夓潃 1攵勱赴 雽�牍� 10% 靹膘灔頄堨姷雼堧嫟.
欤检殧 靹标臣搿滊姅 NEXLETOL庐鞚� 2040雲勱箤歆� 氤错樃頃橂姅 靹� 瓯挫潣 ANDA 於滌洂鞛愳檧鞚� 頃╈潣 觳搓舶, 攴鸽Μ瓿� 須岇偓 斓滌磮鞚� 鞓侅梾鞚挫澋 攵勱赴(1,500毵� 雼煬) 雼劚鞚� 韽暔霅╇媹雼�. 鞐愳姢韼橂Μ鞓潃 鞚茧掣, 鞙犽熃, 旌愲倶雼�, 鞚挫姢霛检棙, 順胳＜/雺挫霝滊摐鞐愳劀 韺岉姼雱堨嫮鞚� 韱淀暣 旮�搿滊矊 頇曥灔鞚� 鞚措（鞐堨溂氅�, 鞙犽熃 搿滌棿韹� 靾橃澋鞚� 鞝勲秳旮� 雽�牍� 30% 歃濌皜頃� 1,360毵� 雼煬毳� 旮半頄堨姷雼堧嫟.
須岇偓電� 2026雲� 1攵勱赴攵�韯� 歆�靻� 臧�電ロ暅 靾橃澋靹膘潉 雼劚頃� 瓴冹溂搿� 旮半寑頃橂┌, 2025雲� 鞓侅梾牍勳毄 臧�鞚措崢鞀るゼ 2鞏� 1,500毵寏2鞏� 3,500毵� 雼煬搿� 鞙犾頃橁碃 鞛堨姷雼堧嫟.
Esperion (NASDAQ : ESPR) a annonc茅 de solides r茅sultats financiers pour le deuxi猫me trimestre 2025, avec un chiffre d'affaires total en hausse de 12 % en glissement annuel, atteignant 82,4 millions de dollars. Les revenus nets des produits aux 脡tats-Unis ont augment茅 de 42 % pour atteindre 40,3 millions de dollars, tandis que les 茅quivalents totaux d鈥檕rdonnances en pharmacie ont progress茅 de 10 % par rapport au premier trimestre.
Parmi les r茅alisations cl茅s figurent des accords de r猫glement avec trois d茅posants ANDA prot茅geant NEXLETOL庐 jusqu鈥檈n 2040, ainsi que le premier trimestre b茅n茅ficiaire en termes de r茅sultat d鈥檈xploitation pour la soci茅t茅 (15,0 millions de dollars). Esperion a 茅tendu sa pr茅sence mondiale gr芒ce 脿 des partenariats au Japon, en Europe, au Canada, en Isra毛l et en Australie/Nouvelle-Z茅lande, avec des revenus de redevances europ茅ennes en hausse de 30 % s茅quentiellement, atteignant 13,6 millions de dollars.
La soci茅t茅 pr茅voit d鈥檃tteindre une rentabilit茅 durable 脿 partir du premier trimestre 2026 et maintient ses pr茅visions de d茅penses d鈥檈xploitation pour 2025 entre 215 et 235 millions de dollars.
Esperion (NASDAQ: ESPR) meldete starke Finanzergebnisse f眉r das zweite Quartal 2025, mit einem Gesamtumsatz, der im Jahresvergleich um 12 % auf 82,4 Millionen US-Dollar wuchs. Der Nettoumsatz mit Produkten in den USA stieg um 42 % auf 40,3 Millionen US-Dollar, w盲hrend die Gesamtzahl der Einzelhandelsverschreibungs盲quivalente im Vergleich zum ersten Quartal um 10 % zunahm.
Zu den wichtigsten Erfolgen z盲hlen Vergleichsvereinbarungen mit drei ANDA-Antragstellern, die NEXLETOL庐 bis 2040 sch眉tzen, sowie das erste Quartal mit operativem Gewinn des Unternehmens (15,0 Millionen US-Dollar). Esperion expandierte global durch Partnerschaften in Japan, Europa, Kanada, Israel und Australien/Neuseeland, wobei die europ盲ischen Lizenzgeb眉hren im Quartalsvergleich um 30 % auf 13,6 Millionen US-Dollar stiegen.
Das Unternehmen erwartet, ab dem ersten Quartal 2026 nachhaltige Profitabilit盲t zu erreichen und h盲lt seine Prognose f眉r die Betriebsausgaben 2025 im Bereich von 215 bis 235 Millionen US-Dollar aufrecht.
- First quarter of operating income ($15.0M) from ongoing business in company history
- U.S. net product revenue grew 42% year-over-year to $40.3M
- Settlement agreements with three ANDA filers protecting NEXLETOL patent until 2040
- European royalty revenue increased 30% sequentially to $13.6M
- Total retail prescription equivalents increased 10% from first quarter
- Over 80% approval rates in targeted business
- Expanded global presence through new partnerships in multiple territories
- Net loss of $4.8M in Q2 2025
- Total revenue decreased 30% for six months YTD compared to 2024
- Cash and cash equivalents declined to $86.1M from $144.8M in December 2024
Insights
Esperion shows strong 42% US revenue growth, achieves first-ever operating profit, and secures patent protection until 2040.
Esperion's Q2 2025 results demonstrate substantial commercial momentum for its bempedoic acid franchise. The 12% year-over-year revenue growth to
The patent settlement agreements with three ANDA filers represent a significant strategic win, extending exclusivity for NEXLETOL until 2040 鈥� substantially longer than typically achieved in such settlements. This protection preserves Esperion's revenue runway for its flagship product for 15 more years, considerably enhancing long-term valuation potential.
Most notable is Esperion achieving its first-ever quarter of operating income (
The company's expanding global footprint through partnerships in Japan, Canada, Israel, and Australia/New Zealand opens additional revenue opportunities. The Japanese approval expected H2 2025 is particularly significant given the substantial market size and Otsuka's commercial capabilities.
From an operational perspective, Esperion has demonstrated disciplined cost management with R&D expenses decreasing 37% year-over-year to
鈥� Q2 2025 Total Revenue Grew
鈥� Q2 2025 U.S. Net Product Revenue Grew
鈥� Total Retail Prescription Equivalents Increased
鈥� Reached Settlement Agreements with Three ANDA Filers Not to Market Generic Versions of NEXLETOL庐 (bempedoic acid) Prior to 2040 鈥�
鈥� First Quarter of Operating Income from Ongoing Business with Plans for Sustainable Profitability Starting in Q1 2026 鈥�
鈥� Conference Call and Webcast Today at 8:00 a.m. ET 鈥�
ANN ARBOR, Mich., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today reported financial results for the second quarter ended June 30, 2025, and provided a business update.
鈥淥ur second quarter results reflect the strength of our commercial execution and the growing adoption of our bempedoic acid therapies in cardiovascular disease prevention. With more than
鈥淎s we advance our growing leadership in cardiovascular diseases, we are proud to welcome Robert Hoffman and Craig Thompson, both seasoned executives with a wealth of commercial and operational expertise, to our Board of Directors,鈥� added Koenig.
Second Quarter 2025 Key Accomplishments and Recent Highlights
Advancing the U.S. Commercial Strategy
- Reached settlement agreements with three ANDA filers not to market generic version of NEXLETOL庐 (bempedoic acid) until 2040.
- Continued to reinforce our differentiated cardiovascular (CV) risk reduction data in Primary Prevention and statin intolerance through both our sales force and healthcare provider (HCP) digital channels.
- Nearly one quarter of prescriptions were written by physicians reached through digital touchpoints only.
- Established strong branding within statin intolerant population with new marketing campaign focused on, 鈥淐an鈥檛 take a statin? Make NEXLIZET happen!鈥�.
- Strengthened access and reimbursement support for NEXLETOL and NEXLIZET庐 (bempedoic acid and ezetimibe), driving greater confidence among payers and HCPs.
- Additions to the Company鈥檚 field reimbursement team have made great strides in supporting our growing prescriber base by educating over 1,100 target prescribers on NEXLETOL and NEXLIZET鈥檚 favorable reimbursement landscape. This was evident by an increase in all targeted business approval rates to over
80% . - Increased total retail prescription equivalents by approximately
10% and grew the number of healthcare practitioners writing prescriptions for NEXLETOL and NEXLIZET to more than 28,000 in the second quarter of 2025.听听
Global Expansion
- The Company鈥檚 partner in Japan, Otsuka Pharmaceutical Co., Ltd. is on track for expected approval and National Health Insurance pricing in the second half of 2025.
- Esperion鈥檚 European partner Daiichi Sankyo Europe (DSE) continues to show strong revenue growth and market penetration for NILEMDO庐听(bempedoic acid) and NUSTENDI庐听(bempedoic acid and ezetimibe), having surpassed the 500,000-patient mark during the second quarter.
- Royalty revenue increased
30% sequentially to$13.6 million , continuing to underscore the ongoing opportunity in Europe for sales of NILEMDO and NUSTENDI. - Advanced multiple processes for the technology transfer for manufacturing of NILEMDO and NUSTENDI to DSE, with certain working capital benefits expected in 2025.
- Royalty revenue increased
- Partnered with HLS Therapeutics for the exclusive rights to commercialize NEXLETOL and NEXLIZET in Canada. The Company鈥檚 previously filed New Drug Submissions to Health Canada are on track for review with an expected market approval in the fourth quarter of 2025.
- The Company and its partner in Israel, Neopharm Israel, remain on track for market approval of NEXLETOL and NEXLIZET in the first half of 2026.
- CSL Seqirus, the Company鈥檚 partner in Australia and New Zealand, filed a marketing application in Australia for NEXLETOL and NEXLIZET in July 2025, and expects market approval in Q4 2026.
Second Quarter and YTD 2025 Financial Results
Revenue
- Total revenue for the three and six months ended June 30, 2025 was
$82.4 million and$147.4 million , respectively, compared to$73.8 million and$211.6 million for the comparable periods in 2024, an increase of12% and a decrease of30% , respectively. Excluding the one-time settlement agreement milestones received in the three months ended June 30, 2024, total revenue grew69% . - U.S. net product revenue for the three and six months ended June 30, 2025 was
$40.3 million and$75.2 million , respectively, compared to$28.3 million and$53.1 million , for the comparable periods in 2024, an increase of42% for each respective period. - Collaboration revenue was
$42.1 million and$72.2 million for the three and six months ended June 30, 2025, respectively, compared to$45.5 million and$158.5 million for the comparable periods in 2024, a decrease of approximately7% and54% , respectively.- The decreases were driven by the settlement agreement milestone with DSE received in the three and six months ended June 30, 2024, offset partially by increases in royalty sales within our partner territories and product sales to our collaboration partners from our supply agreements. Excluding the settlement agreement milestones, collaboration revenue grew approximately
105% and102% from the comparable periods.
- The decreases were driven by the settlement agreement milestone with DSE received in the three and six months ended June 30, 2024, offset partially by increases in royalty sales within our partner territories and product sales to our collaboration partners from our supply agreements. Excluding the settlement agreement milestones, collaboration revenue grew approximately
R&D Expenses
- Research and development expenses for the three and six months ended June 30, 2025 were
$7.2 million and$19.8 million , respectively, compared to$11.5 million and$24.9 million for the comparable periods in 2024, a decrease of37% and20% , respectively.- The decrease in research and development expenses was primarily attributable to decreased costs for ongoing clinical studies and decreased compensation costs, including bonus, stock compensation and consulting.
Selling, General and Administrative (SG&A) Expenses
- Selling, general and administrative expenses for the three and six months ended June 30, 2025 were
$39.5 million and$82.5 million , respectively, compared to$44.2 million and$86.2 million for the comparable periods in 2024, a decrease of11% and4% , respectively.- The decrease was primarily related to decreased media and marketing costs.
Net Income (Loss). For the three and six months ended June 30, 2025, the Company had net losses of
Net Income (Loss) Per Share. Basic and diluted net losses per share for the three and six months ended June 30, 2025 were
Cash and Cash Equivalents. As of June 30, 2025, cash and cash equivalents totaled
The Company ended the quarter with approximately 200.2 million shares of common stock outstanding, excluding 2.0 million treasury shares.
2025 Financial Outlook
The Company reiterates its expectation for full year 2025 operating expenses to be in the range of
Conference Call and Webcast Information
Esperion will host a conference call and webcast at 8:00 a.m. ET to discuss the financial results and business progress.
A live audio webcast can be accessed on the investor and media section of the Esperion . The webcast replay will be available approximately two hours after completion of the call and will be archived on the Company's website for approximately 90 days.
INDICATION
NEXLIZET and NEXLETOL are indicated:
- The bempedoic acid component of NEXLIZET and NEXLETOL is indicated to reduce the risk of myocardial infarction and coronary revascularization in adults who are unable to take recommended statin therapy (including those not taking a statin) with:
- established cardiovascular disease (CVD), or
- at high risk for a CVD event but without established CVD.
- As an adjunct to diet:
- NEXLIZET, alone or in combination with other LDL-C lowering therapies, to reduce LDL-C in adults with primary hyperlipidemia, including HeFH.
- NEXLETOL, in combination with other LDL-C lowering therapies, or alone when concomitant LDL-C lowering therapy is not possible, to reduce LDL-C in adults with primary hyperlipidemia, including HeFH.
IMPORTANT SAFETY INFORMATION
NEXLIZET and NEXLETOL are contraindicated in patients with a prior hypersensitivity to bempedoic acid or ezetimibe or any of the excipients. Serious hypersensitivity reactions including anaphylaxis, angioedema, rash, and urticaria have been reported.
Hyperuricemia: Bempedoic acid, a component of NEXLIZET and NEXLETOL, may increase blood uric acid levels, which may lead to gout. Hyperuricemia may occur early in treatment and persist throughout treatment, returning to baseline following discontinuation of treatment. Assess uric acid levels periodically as clinically indicated. Monitor for signs and symptoms of hyperuricemia, and initiate treatment with urate-lowering drugs as appropriate.
Tendon Rupture: Bempedoic acid, a component of NEXLIZET and NEXLETOL, is associated with an increased risk of tendon rupture or injury. Tendon rupture may occur more frequently in patients over 60 years of age, in those taking corticosteroid or fluoroquinolone drugs, in patients with renal failure, and in patients with previous tendon disorders. Discontinue NEXLIZET or NEXLETOL at the first sign of tendon rupture. Consider alternative therapy in patients who have a history of tendon disorders or tendon rupture.
The most common adverse reactions in the primary hyperlipidemia trials of bempedoic acid, a component of NEXLIZET and NEXLETOL, in 鈮�
Adverse reactions reported in 鈮�
In the primary hyperlipidemia trials of NEXLIZET, the most commonly reported adverse reactions (incidence 鈮�
The most common adverse reactions in the cardiovascular outcomes trial for bempedoic acid, a component of NEXLIZET and NEXLETOL, at an incidence of 鈮�
Discontinue NEXLIZET or NEXLETOL when pregnancy is recognized unless the benefits of therapy outweigh the potential risks to the fetus. Because of the potential for serious adverse reactions in a breast-fed infant, breastfeeding is not recommended during treatment with NEXLIZET or NEXLETOL.
Report pregnancies to Esperion Therapeutics, Inc. Adverse Event reporting line at 1-833-377-7633.
Please see full Prescribing Information for and .
About Esperion Therapeutics
Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company focused on bringing new medicines to market that address unmet needs of patients and healthcare professionals. The Company developed and is commercializing the only U.S. Food and Drug Administration (FDA) approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease and are struggling with elevated low density lipoprotein cholesterol (LDL-C). These medications are supported by the nearly 14,000 patient CLEAR Cardiovascular Outcomes Trial. Esperion continues to build on its success with its next generation program which is focused on developing ATP citrate lyase inhibitors (ACLYi). New insights into the structure and function of ACLYi fully enables rational drug design and the opportunity to develop highly potent and specific inhibitors with allosteric mechanisms.
Esperion continues to evolve into a leading global biopharmaceutical company through commercial execution, international partnerships and collaborations and advancement of its pre-clinical pipeline. For more information, visit and follow Esperion on and .
Forward-Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding marketing strategy and commercialization plans, current and planned operational expenses, expected profitability, future operations, commercial products, clinical development, including the timing, designs and plans for the CLEAR Outcomes study and its results, plans for potential future product candidates, financial condition and outlook, including expected cash runway and profitability, and other statements containing the words 鈥渁nticipate,鈥� 鈥渂elieve,鈥� 鈥渆stimate,鈥� 鈥渆xpect,鈥� 鈥渋ntend,鈥� 鈥渕ay,鈥� 鈥減lan,鈥� 鈥減redict,鈥� 鈥減roject,鈥� 鈥渟uggest,鈥� 鈥渢arget,鈥� 鈥減otential,鈥� 鈥渨ill,鈥� 鈥渨ould,鈥� 鈥渃ould,鈥� 鈥渟hould,鈥� 鈥渃ontinue,鈥� and similar expressions. Any express or implied statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause Esperion鈥檚 actual results to differ significantly from those projected, including, without limitation, the net sales, profitability, and growth of Esperion鈥檚 commercial products, clinical activities and results, supply chain, commercial development and launch plans, the outcomes and anticipated benefits of legal proceedings and settlements, and the risks detailed in Esperion鈥檚 filings with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Esperion disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by law.
Esperion Contact Information:
Investors:
Alina Venezia
(734) 887-3903
Media:
Tiffany Aldrich
(616) 443-8438
| 听 | |||||||
| Esperion Therapeutics, Inc. | |||||||
| 听 | |||||||
| Balance Sheet Data | |||||||
| (In thousands) | |||||||
| (Unaudited) | |||||||
| 听 | |||||||
| 听 | June 30, 2025 | 听 | December 31, 2024 | ||||
| Cash and cash equivalents | $ | 86,061 | 听 | 听 | $ | 144,761 | 听 |
| Working capital | 听 | 51,733 | 听 | 听 | 听 | 91,765 | 听 |
| Total assets | 听 | 355,019 | 听 | 听 | 听 | 343,821 | 听 |
| Royalty sale liability | 听 | 295,912 | 听 | 听 | 听 | 293,610 | 听 |
| Convertible notes, net of issuance costs | 听 | 151,764 | 听 | 听 | 听 | 151,320 | 听 |
| Long-term debt | 听 | 146,452 | 听 | 听 | 听 | 140,971 | 听 |
| Common stock | 听 | 200 | 听 | 听 | 听 | 196 | 听 |
| Accumulated deficit | 听 | (1,646,275 | ) | 听 | 听 | (1,601,029 | ) |
| Total stockholders' deficit | 听 | (425,575 | ) | 听 | 听 | (388,722 | ) |
| 听 | |||||||
| Esperion Therapeutics, Inc. | |||||||||||||||
| 听 | |||||||||||||||
| Statement of Operations | |||||||||||||||
| (In thousands, except share and per share data) | |||||||||||||||
| (Unaudited) | |||||||||||||||
| 听 | |||||||||||||||
| 鈥� | Three Months Ended June 30, | 听 | Six Months Ended June 30, | ||||||||||||
| 鈥� | 听 | 2025 | 听 | 听 | 听 | 2024 | 听 | 听 | 听 | 2025 | 听 | 听 | 听 | 2024 | 听 |
| Revenues: | 鈥� | 听 | 听 | 听 | 鈥� | 听 | 听 | ||||||||
| Product sales, net | $ | 40,274 | 听 | 听 | $ | 28,302 | 听 | 听 | $ | 75,187 | 听 | 听 | $ | 53,058 | 听 |
| Collaboration revenue | 听 | 42,111 | 听 | 听 | 听 | 45,532 | 听 | 听 | 听 | 72,193 | 听 | 听 | 听 | 158,511 | 听 |
| Total Revenues | 听 | 82,385 | 听 | 听 | 听 | 73,834 | 听 | 听 | 听 | 147,380 | 听 | 听 | 听 | 211,569 | 听 |
| 鈥� | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||||||
| Operating expenses: | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||||||
| Cost of goods sold | 听 | 20,609 | 听 | 听 | 听 | 15,609 | 听 | 听 | 听 | 52,147 | 听 | 听 | 听 | 25,684 | 听 |
| Research and development | 听 | 7,238 | 听 | 听 | 听 | 11,461 | 听 | 听 | 听 | 19,795 | 听 | 听 | 听 | 24,864 | 听 |
| Selling, general and administrative | 听 | 39,509 | 听 | 听 | 听 | 44,185 | 听 | 听 | 听 | 82,505 | 听 | 听 | 听 | 86,173 | 听 |
| Total operating expenses | 听 | 67,356 | 听 | 听 | 听 | 71,255 | 听 | 听 | 听 | 154,447 | 听 | 听 | 听 | 136,721 | 听 |
| 鈥� | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||||||
| Income (loss) from operations | 听 | 15,029 | 听 | 听 | 听 | 2,579 | 听 | 听 | 听 | (7,067 | ) | 听 | 听 | 74,848 | 听 |
| 鈥� | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||||||
| Interest expense | 听 | (20,486 | ) | 听 | 听 | (13,723 | ) | 听 | 听 | (39,917 | ) | 听 | 听 | (27,747 | ) |
| Loss on extinguishment of debt | 听 | 鈥� | 听 | 听 | 听 | (53,235 | ) | 听 | 听 | 鈥� | 听 | 听 | 听 | (53,235 | ) |
| Other income, net | 听 | 666 | 听 | 听 | 听 | 2,454 | 听 | 听 | 听 | 1,738 | 听 | 听 | 听 | 5,231 | 听 |
| Net loss | $ | (4,791 | ) | 听 | $ | (61,925 | ) | 听 | $ | (45,246 | ) | 听 | $ | (903 | ) |
| 鈥� | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||||||
| Net loss per common share - basic and diluted | $ | (0.02 | ) | 听 | $ | (0.33 | ) | 听 | $ | (0.23 | ) | 听 | $ | (0.01 | ) |
| 鈥� | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||||||
| Weighted-average shares outstanding - basic and diluted | 听 | 197,546,239 | 听 | 听 | 听 | 188,793,816 | 听 | 听 | 听 | 196,841,011 | 听 | 听 | 听 | 179,026,191 | 听 |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||||||
FAQ
What were Esperion's (ESPR) Q2 2025 earnings results?
When does Esperion (ESPR) expect to achieve sustainable profitability?
What is the significance of Esperion's ANDA settlements for NEXLETOL?
How is Esperion's European business performing in 2025?
What are Esperion's operating expense projections for 2025?
